drugset / Trial / NCT07511023
Phase 2 Trial Of Sacituzumab Tirumotecan For Treatment Of Refractory Metastatic Or Unresectable Squamous Cell Carcinoma Of The Anus/Rectum
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To look at the effectiveness of sacituzumab tirumotecan (MK-2870) in treating participants with treatment-refractory unresectable and/or metastatic anal/rectal cancer.
Timeline
- Start
- 2026-09-25
- Primary completion
- 2031-03-01
- Completion
- 2033-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sacituzumab Tirumotecan | Other / unclassified | — | Intravenous |